

This is an English translation of the Swedish original. In case of discrepancies, the Swedish original shall prevail.

Press release | Umeå March 1, 2022

Lipigon: Prioritized patent application for Lipisense in US is confirmed

Lipigon Pharmaceuticals AB ("Lipigon"), which is developing therapeutics for lipid-related diseases, today announced that the patent for Lipigon's drug candidate Lipisense is subject to prioritized application in the US and that this application was confirmed by the U.S. Patent and Trademark Office ("USPTO") on February 18, 2022.

The prioritized application allows the applicant to reach a final disposition within 12 months—a process that can otherwise take several years. To have the patent granted earlier than in the regular process is of high value to Lipigon and is seen as one of the key preparations for licensing discussions.


Lipisense is a drug candidate for the treatment of diseases with abnormal levels of lipids in the blood, primarily triglycerides, and a first-in-class treatment with a unique mechanism of action. Elevated triglyceride levels in the blood are a risk factor present in several diseases. Lipisense has the potential to normalize blood triglyceride levels. The patient population with uncontrolled elevated triglycerides is large and heterogeneous—comprising patients with rare genetic disorders to large patient groups, such as type 2 diabetics.

CEO Stefan K. Nilsson comments:

"This is a major milestone on the journey forward for Lipigon and Lipisense, as patents are one of the key factors in drug development. To have a faster process for the US patent is significant risk mitigation and opens for early business opportunities. During the fall and winter, we have observed a great deal of interest in RNA-based drugs along with several important deals."

About Lipisense

The drug candidate is an RNA therapeutics that prevents the cells from producing the disease-promoting target protein ANGPTL4 by destroying the protein-coding RNA before the target protein has been formed. The target gene has a strong genetic association to plasma lipid levels and related diseases, such as type 2 diabetes and cardiovascular disease.





For more information, please contact:

Stefan K. Nilsson, CEO, Lipigon


Email: stefan@lipigon.se

Phone: +46 705 78 17 68

About Lipigon

Lipigon develops novel therapeutics for patients with lipid metabolism disorders. The company is based on over 50 years of lipid research at Umeå University, Sweden. Lipigon's initial focus is on orphan drugs and niche indications, but in the long term, the company will have the opportunity to target broader indications in the area, such as diabetes and cardiovascular disease. Lipigon's pipeline includes four active projects: the RNA-drug Lipisense for treatment of hypertriglyceridemia; an RNA-drug for treatment of acute respiratory distress syndrome; a gene therapy treatment for the rare disease lipodystrophy, together with Combigene AB (publ); and a small molecule program for the treatment of dyslipidemia in collaboration with HitGen (Inc).

The company's share (LPGO) is traded on the Nasdaq First North Growth Market. Certified Adviser is G&W Fondkommission, email: ca@gwkapital.se, phone: +46 8 503 000 50.



Tvistevägen 48 C, SE-90736 Umeå, Sweden

Tel: +46(0)705781768, info@lipigon.se

Org.nr: 556810-9077

lipigon.se